Biotech Startups

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases. The company's pipeline focuses on novel small-molecule and biologic drugs addressing metabolic dysfunction and cardiovascular health.

2 investors

RNA Diagnostics is a clinical-stage molecular diagnostics company developing a predictive biomarker platform to guide personalized cancer therapy management. The company's technology helps physicians optimize treatment decisions for cancer patients, particularly in breast cancer, to improve outcomes and reduce healthcare costs.

2 investors

RNAiSSANCE AG develops RNAi-based solutions for agricultural pest control, using biomanufacturing, strain development, and entomology research. The company focuses on discovery and production of RNA interference technology for crop protection.

2 investors

Instem provides SaaS platforms for life sciences research organizations, covering in silico analytics, study management, regulatory submission support, and clinical trial analytics to accelerate drug and therapy development.

2 investors

Romix Bio develops technology to generate deeper insights into disease biology and therapeutic activity. The page provides minimal detail about its specific products or offerings.

2 investors

Rosalind Dx is a diagnostics company developing and commercializing medical tests, with team experience that includes launching a prenatal test.

2 investors

Rose Pharma is a pharmaceutical company developing therapies in gastroenterology and metabolic disorders. Led by experienced executives from major pharmaceutical firms, the company operates in the medtech/biotech sectors.

2 investors

Rosebud Biosciences develops therapies for rare genetic diseases in children by creating organoid models that replicate patient genetic mutations and using drug screening to identify potential cures. The company uses human-derived organoids combined with robotics and machine learning to accelerate drug discovery across cardiac, hepatic, neural, and kidney disease targets.

2 investors

RS Research develops polymer-drug conjugates for targeted chemotherapy and theranostics in oncology, aiming to improve the therapeutic index in cancer treatment. The company's platform technology addresses the efficacy-toxicity trade-off challenge in targeted therapies.

2 investors

RyCarma Therapeutics develops a novel drug class called Rycals to treat orphan skeletal muscle and cardiac diseases, building on foundational cardiovascular research and drug-delivery technologies.

2 investors

Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes. The company targets patients with COPD who are inadequately managed by existing medications and pulmonary rehabilitation.

2 investors

S-Biomedic develops microbiome-based skincare products designed to restore the skin's healthy microbial balance for people with certain skin conditions. The company applies probiotic science to cosmetic skincare solutions.

2 investors

SafeHeal is a medical device manufacturer developing anastomosis protection devices for colorectal surgery. Its investigational device, Colovac, aims to protect the anastomosis after colorectal surgery and eliminate the need for diverting ostomy in patients undergoing colectomy, serving colorectal surgeons and cancer patients.

2 investors

SageMedic is a California-licensed clinical laboratory providing cancer treatment testing and diagnostics through its SAGE Oncotest™ platform. The company serves oncologists and cancer patients seeking more effective preoperative care approaches.

2 investors

SAGES develops bio-based dyes derived from phytochemical extractions that replace synthetic dyes in textile and materials applications, achieving industry-standard performance while reducing carbon emissions and eliminating toxic chemical pollution. The company targets fashion brands, manufacturers, and designers seeking sustainable colouration solutions.

2 investors

Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms shared across multiple viruses. Its lead programs are self-administered, nasally inhaled fusion inhibitors for respiratory viruses, including a pan-coronavirus drug for immunocompromised patients and a combined flu/COVID/RSV "tripledemic" antiviral.

2 investors

Samsara BioCapital is a venture capital firm that invests in therapeutic and biotech companies, backing scientific teams developing new drugs and medical treatments.

2 investors

SanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.

2 investors

Sanodyne Therapeutics develops SNT-001, an orally administered small-molecule compound intended to treat peripheral neuropathy and neuropathic pain. The drug uses a distinct mechanism of action and is positioned as a potential root-cause therapy for pain.

2 investors

Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.

2 investors

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

2 investors

Sarsia is a venture capital and investment firm that backs early-stage companies in life sciences, technology, energy, and sustainability sectors. The firm draws on a team with academic and industry expertise spanning biology, physics, engineering, pharmacology, and finance.

2 investors

Sauvie is developing a protein discovery platform in the biological intelligence space. The company's website is a pre-launch placeholder with limited details.

2 investors

SavranTech is a diagnostics company developing non-invasive, cell-based diagnostic tests for women's health, starting with preeclampsia, and spanning maternal health, prenatal care, and oncology. Its patented platform serves clinicians and healthcare in the women's health diagnostics category.

2 investors